Cardiva Medical, the Sunnyvale, Calif.-based company known for its vascular closure system, which received FDA approval in February, has raised nearly all of the $3.5 million it seeks, waiting on only $2,367 to close out the deal, according to the regulatory filing it made with the SEC July 29.
The company could not be reached for comment.
About this time last year, the company completed the third tranche of Series 2 financing.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Officers and directors according to the filing include: President and CEO Charles Maroney, who previously was president and CEO of Coalescent, which Medtronic acquired; Rick Anderson, managing director at PTV Sciences, who was formerly company group chairman at Johnson & Johnson; VP of Operations Justin Ballotta; VP of Clinical Affairs Marlys Chellew; Matthew Crawford, founding managing director at PTV Sciences, who was previously a partner at a venture capital firm in North Carolina; VP of Regulatory Affairs Michael Daniel; CFO and VP of Finance Malcolm Farnsworth, who was previously CFO at POINT Biomedical and CFO at Gynecare, which Johnson & Johnson acquired after its IPO; Dr. George Lee; founder and former CEO Augustine Lien; Director Sylvia Liu; VP of Sales John McCurdy; Director John Wilkerson, Founder and Senior Advisor at Galen Partners; and Co-Founder and VP of R&D Zia Yassinzadeh, most recently of RITA Medical Systems and Gynecare.